MINIMAKI_HEARTTEAM: Clinical and ethical requirements of AI-based patient specific mitral valve therapies in the heart team
Recruiting
- Conditions
- Z95Presence of cardiac and vascular implants and grafts
- Registration Number
- DRKS00029520
- Lead Sponsor
- Fraunhofer MEVIS und Deutsches Herzzentrum Berlin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Physicians of the Heart Team of the Clinic for Cardiovascular Medicine
Exclusion Criteria
There is no informed consent.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical requirements, ethical requirements<br>Conducted by means of participatory observations of preoperative meetings and group discussions with members of the heart team.
- Secondary Outcome Measures
Name Time Method Communication, Interaction, Clinical Decision-Making<br>Conducted by means of participatory observations of preoperative meetings and group discussions with members of the heart team.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie AI-based patient-specific mitral valve therapies in DRKS00029520?
How does AI-based mitral valve therapy compare to standard-of-care in patients with Z95 cardiac implants?
What biomarkers are used for patient selection in AI-driven mitral valve treatment strategies?
What adverse events are associated with AI-based therapies for mitral valve disease in cardiac implant patients?
How do AI-based mitral valve therapies integrate with existing cardiac surgical and interventional approaches?